Business Context and Reporting Period
This Form 8-K filing by Matinas Biopharma Holdings, Inc. (MTNB) reports on events occurring on January 22, 2026. The filing addresses a significant change in executive leadership regarding the Chief Financial Officer (CFO) position.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and personnel changes rather than financial performance data.
Material Changes
- Departure of CFO: Keith Kucinski resigned as Chief Financial Officer effective January 17, 2026, to pursue other opportunities.
- Appointment of Interim CFO: On January 22, 2026, the Board appointed Jerome D. Jabbour as Interim Chief Financial Officer.
- Role Consolidation: Mr. Jabbour will assume the duties of principal financial officer and principal accounting officer while continuing his existing roles as Chairman of the Board, President, and Chief Executive Officer.
Guidance, Outlook, and Management Commentary
The filing contains no financial guidance, outlook, or discussion of risks and contingencies related to the company's business operations. Management commentary is limited to the biographical background of Mr. Jabbour and the confirmation that his compensatory terms remain unchanged. There are no unusual items or undisclosed arrangements associated with this appointment.
Investor Verification Checklist
- Verify the timeline for the search and appointment of a permanent Chief Financial Officer.
- Confirm that Mr. Jabbour's dual role as CEO and Interim CFO does not impact the company's internal financial controls or reporting timelines.
- Review upcoming quarterly filings to assess any operational impact resulting from the CFO transition.